Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, announced the appointment of Christopher Peetz to its Board of Directors, effective from July 15, 2026.
Peetz is co-founder and Chief Executive Officer (CEO) of Mirum Pharmaceuticals Inc. (MIRM), where he has led the company's growth as a rare disease biopharmaceutical firm since its founding in 2018. He also currently serves as entrepreneur-in-residence at Frazier Life Sciences.
Previously, Peetz served as CEO of Flashlight Therapeutics and as Chief Financial Officer (CFO) and Head of Corporate Development at Tobira Therapeutics Inc. (TBRA) prior to its acquisition by Allergan.
Earlier in his career, he held leadership roles at Jennerex Biotherapeutics and Onyx Pharmaceuticals Inc (ONXX), planning corporate strategy, marketing, corporate development, and finance. He also served on the Board of Directors of Alpine Immune Sciences, Inc. (ALPN) until it was acquired by Vertex Pharmaceuticals, Inc (VRTX).
ARQT is currently trading up 0.14% at $27.82.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.